Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Bridging the Brain Disease Knowledge Gap Through Computational Modeling and Systems Biology
Vitamin D3 Receptor ( VDR ) Gene rs2228570 (Fok1) and rs731236 (Taq1) Variants Are Not Associated with the Risk for Multiple Sclerosis: Results of a New Study and a Meta-Analysis.
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Assessment of cerebral venous return by a novel plethysmography method.
Olive oil phenols and neuroprotection.
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
Transcriptomics: mRNA and alternative splicing.
[Cognitive impairment in demyelinating disease].
Biochemical Markers of Autoimmune Diseases of the Nervous System.
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.
Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation.
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: A cross-sectional study.
Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome.
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.
Long-term follow-up of vanishing tumors in the brain: How should a lesion mimicking primary CNS lymphoma be managed?
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Pages